论文部分内容阅读
目的:探索新型雌激素受体G蛋白耦联受体30(G protein coupled receptor 30,GPR30)在人上皮性卵巢癌发生发展中的作用。方法:采用免疫组织化学SP法检测30例上皮性卵巢癌组织中GPR30、增殖相关基因c-fos和cyclinD1的表达,并以9例良性卵巢肿瘤、4例正常卵巢组织作对照。结果:GPR30在上皮性卵巢癌的表达水平(80.0%)显著高于良性卵巢肿瘤(44.4%)和正常卵巢组织(25.0%)(P<0.01;P<0.05)。GPR30和c-fos的表达与上皮性卵巢癌的病理类型、FIGO分期有关,在浆液性囊腺癌、FIGOⅢ-Ⅳ期的表达水平显著升高(P<0.05)。未见cyclinD1的表达与上皮性卵巢癌临床病理参数的关系(P>0.05)。上皮性卵巢癌中GPR30与c-fos、cyclinD1的表达具有正相关性(P<0.01;P<0.05)。结论:GPR30可能通过c-fos、cyclinD1促进卵巢癌增殖,参与上皮性卵巢癌的发生、发展。
Objective: To explore the role of the novel estrogen receptor G protein coupled receptor 30 (GPR30) in the development of human epithelial ovarian cancer. Methods: The expressions of GPR30, c-fos and cyclinD1 in 30 cases of epithelial ovarian cancer were detected by immunohistochemical SP method. Nine cases of benign ovarian tumor and 4 cases of normal ovarian tissue were used as controls. Results: The expression of GPR30 in epithelial ovarian cancer (80.0%) was significantly higher than that in benign ovarian tumors (44.4%) and normal ovarian tissues (25.0%) (P <0.01; P <0.05). The expression of GPR30 and c-fos was correlated with the pathological type of epithelial ovarian cancer and FIGO staging. In serous cystadenocarcinoma, the expression level of FIGOⅢ-Ⅳ was significantly increased (P <0.05). No correlation was found between the expression of cyclinD1 and clinicopathological parameters of epithelial ovarian cancer (P> 0.05). There was a positive correlation between the expression of GPR30 and c-fos, cyclinD1 in epithelial ovarian cancer (P <0.01; P <0.05). Conclusion: GPR30 may promote the proliferation of ovarian cancer through c-fos and cyclinD1 and participate in the occurrence and development of epithelial ovarian cancer.